|
|
| YOU ARE HERE: | Home > Market Trades & Forecasts > Stock Picks |
Enterprise Products - MLP (EPD) - Bull of the Day
Wed, 22 Feb 2012Enterprise Products Partners (EPD), which remains a core holding in an MLP (master limited partnership) portfolio, focuses on projects that generate stable cash flow and contribute to its integrated value chain. We believe the Haynesville Acadian Expansion and Eagle Ford projects will allow Enterprise to take a lead role in the development of natural gas liquids and natural gas infrastructure.
While Enterprise increased its cash flow distribution by 5.1% in the fourth quarter, it also deployed cash in various fee-based development projects that will likely generate operating cash flow to support its future distribution growth. As such, we believe Enterprise is well positioned going forward and view it as an attractive investment.
Thus we maintain our recommendation on Enterprise Products Partners at Outperform. Our $63 target price, 26.0x 2012 earnings per unit, corroborates this view.
ENTERPRISE PROD (EPD): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
ImmunoCellular (IMUC) - Bull of the Day
Tue, 21 Feb 2012ImmunoCellular (IMUC) is a clinical stage biotech company focused on the research and development of innovative cancer therapeutics. The company's lead drug candidate ICT-107 is a next-generation cancer vaccine targeting cancer stem cells to prevent recurrence.
ICT-107 has demonstrated the best clinical data for glioblastoma so far and is under a Phase II trial. ICT-107 holds a high promise for glioblastoma and has potential for other cancers. IMUC also has a pipeline based on its off-the-shelf peptide vaccine technology and monoclonal antibody technology, which ensures sustainable growth for the company.
IMUC is heading in the right direction and poised to deliver shareholder value. We think at this time IMUC should be valued between $200 and $300 million in market cap. Our $7.00 per share price target represents a market cap of $266 million.
IMMUNOCELLULAR (IMUC): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Eastman Chemical Co. (EMN) - Bull of the Day
Fri, 17 Feb 2012Eastman Chemical Co.'s (EMN) fourth-quarter revenues rose 18% year over year to $1.7 billion, driven by increased selling prices and higher sales volumes. The company expects to face certain headwinds in the first half of 2012, but anticipates that there will be more economic activity in the second half of 2012, particularly in the Asia-Pacific and North American regions.
The company expects earnings per share from continuing operations in 2012 to be higher than that of 2011. Eastman Chemical expects to deliver strong results and looks forward to benefit from the recent capacity additions as well as the Sterling and Scandiflex acquisitions.
We, therefore, upgraded our recommendation to Outperform from Neutral with a target price of $65.00. Our $65.00 target price, 13.2x the 2012 EPS, reflects our Outperform view.
EASTMAN CHEM CO (EMN): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Visit these pages for more stock picks:
| Commodities | Dollar | Futues Trading Signals |
| Investment Ideas | Market Trends | Oil |
| Options Trading Signals | Precious Metals | Real Estate |
| S&P 500 | Stock Picks |